Conolidine’s analgesic results stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors within the central anxious program, conolidine modulates alternate molecular targets. A Science Improvements research found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://baltasary107uxc5.wikiexcerpt.com/user